Aclaris Therapeutics, Inc. (ACRS)
$
1.57
-0.02 (-1.27%)
Key metrics
Financial statements
Free cash flow per share
-0.3935
Market cap
170 Million
Price to sales ratio
9.5624
Debt to equity
0
Current ratio
5.0567
Income quality
0.0946
Average inventory
0
ROE
-0.9241
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative drug candidates for immune-inflammatory diseases in the United States. The weighted average number of shares outstanding is 77,296,665.00 highlighting the company's shareholder base. Aclaris operates through two segments: Therapeutics and Contract Research. The Therapeutics segment identifies and develops therapies to meet significant unmet needs in immuno-inflammatory diseases, while the Contract Research segment provides laboratory services. The company reported a net loss of -$132,065,000.00 indicating challenges in its operations. Key products include Zunsemetinib, an MK2 inhibitor targeting moderate to severe rheumatoid and psoriatic arthritis, and ATI-1777, a soft JAK 1/3 inhibitor aimed at moderate to severe atopic dermatitis. Additionally, the company is developing ATI-2138, an ITK/TXK/JAK3 inhibitor for T cell-mediated autoimmune diseases, as well as a Gut-Biased Program for inflammatory bowel disease and ATI-2231, an MK2 inhibitor targeting pancreatic and metastatic breast cancer. The operating income ratio is -7.58 showcasing the company’s operational profitability margin, while the EBITDA sits at -$51,720,000.00 a key measure of operational profitability. Earnings per share (EPS) is reported at -$1.71 reflecting the company's profitability on a per-share basis. In the broader market context, the stock is affordable at $1.59 making it suitable for budget-conscious investors. It has a high average trading volume of 920,654.00 indicating strong liquidity within the market. With a market capitalization of $170,001,170.00 Aclaris is classified as a small-cap player, positioning itself as a key contributor in the Medical - Diagnostics & Research industry that significantly impacts the overall market landscape. Moreover, it belongs to the Healthcare sector, where it drives innovation and growth. The company’s strategic focus on addressing unmet medical needs underscores its role in advancing therapeutic options for patients suffering from chronic conditions.
Is Aclaris Therapeutics, Inc. (ACRS) a good investment?
Investing in Aclaris Therapeutics, Inc. (ACRS) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C-, with a Bullish outlook. Always conduct your own research before investing.
What is Aclaris Therapeutics, Inc. (ACRS)'s stock forecast?
Analysts predict Aclaris Therapeutics, Inc. stock to fluctuate between $1.05 (low) and $5.17 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Aclaris Therapeutics, Inc.'s market capitalization?
As of 2025-07-11, Aclaris Therapeutics, Inc.'s market cap is $170,001,170, based on 108,281,000 outstanding shares.
How does Aclaris Therapeutics, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Aclaris Therapeutics, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Aclaris Therapeutics, Inc. (ACRS) stock?
To buy Aclaris Therapeutics, Inc. (ACRS) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ACRS. Place an order (Market, Limit, etc.).
What is the best time to invest in Aclaris Therapeutics, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did Aclaris Therapeutics, Inc. perform in the last earnings report?
Revenue: $18,720,000 | EPS: -$1.71 | Growth: 34.65%.
Where can I find Aclaris Therapeutics, Inc.'s investor relations reports?
Visit https://www.aclaristx.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Aclaris Therapeutics, Inc.?
You can explore historical data from here
What is the all-time high and low for Aclaris Therapeutics, Inc. stock?
All-time high: $30.38 (2021-04-08) | All-time low: $0.59 (2023-11-13).
What are the key trends affecting Aclaris Therapeutics, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
13 days ago
WAYNE, Pa., June 30, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the Company has been added to the broad-market Russell 3000® and small-cap Russell 2000® Indexes as of the conclusion of the 2025 Russell US Indexes annual reconstitution, effective at the open of US equity markets today, Monday, June 30, 2025. The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of Wednesday, April 30th, ranking them by total market capitalization.
globenewswire.com
17 days ago
WAYNE, Pa., June 26, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that it will provide a corporate presentation during the H.C. Wainwright Inflammation & Immunology Virtual Conference.
globenewswire.com
21 days ago
- Potential Best-In-Class Bispecific Antibody ATI-052 Targets Both Thymic Stromal Lymphopoietin (TSLP) and Interleukin-4 Receptor (IL-4R) - WAYNE, Pa., June 23, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that it has initiated a placebo-controlled Phase 1a/1b program for ATI-052, the Company's potential best-in-class investigational bispecific anti-TSLP/IL-4R antibody.
globenewswire.com
2 months ago
WAYNE, Pa., May 28, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the Company will participate in two upcoming healthcare conferences in June.
globenewswire.com
2 months ago
WAYNE, Pa., May 09, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that Aclaris' Chief Executive Officer Neal Walker and other members of the Aclaris senior leadership team will participate in a fireside chat during the virtual HC Wainwright “HCW@Home” series. The virtual fireside chat will take place on Friday May 16, 2025, at 1:00 PM EDT.
zacks.com
2 months ago
Aclaris Therapeutics (ACRS) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.24 per share a year ago.
globenewswire.com
2 months ago
- Multiple Catalysts in Immuno-Inflammatory Indications Anticipated in 2025 and 2026 - - Expected Cash Runway Extended Through the First Half of 2028 - - Phase 2 Results Received to Date from Chinese Partner CTTQ Provide Clinical Evidence of Enhanced Potency of Bosakitug (ATI-045) and Opportunity for Development Partnerships - - Investigational New Drug (IND) Application for Bispecific Antibody ATI-052 Cleared by U.S. Food and Drug Administration - WAYNE, Pa., May 08, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the first quarter of 2025 and provided a corporate update.
globenewswire.com
2 months ago
WAYNE, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that Jesse Hall, M.D. has been appointed as Chief Medical Officer.
globenewswire.com
4 months ago
WAYNE, Pa., March 04, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the Company will participate in two upcoming healthcare conferences in March. On Tuesday March 11, 2025, at 3:00 PM EDT, Aclaris' Chief Executive Officer Dr. Neal Walker and other members of Aclaris' senior leadership team will participate in a fireside chat during the Leerink Partners Global Healthcare Conference in Miami, Florida.
zacks.com
5 months ago
Aclaris Therapeutics (ACRS) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.30 per share a year ago.
See all news
